Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. demonstrated strong financial performance in the latest quarter, with its active telehealth subscriber base growing by 16% year-over-year to approximately 323,000 by the end of 4Q25, and with a substantial increase of 13,000 net new subscribers added in that quarter alone. The company reported total revenue of $60.2 million, achieving a 12.7% year-over-year growth, while telehealth-specific revenue rose by 17.4% to $47.3 million, showcasing the continued demand for its healthcare services. Additionally, LifeMD benefited from an impressive gross margin expansion to 87%, reflecting a favorable revenue mix and an established foothold in the growing telehealth market.

Bears say

LifeMD Inc. faces significant challenges that may negatively impact its stock outlook, including an inability to meet growth projections for telehealth revenue, as demonstrated by a disappointing quarterly revenue of $60.2 million, which fell short of expectations. The company also reduced its full-year 2025 revenue guidance to $192 million - $193 million following a decline in revenue from its WorkSimplifi segment, suggesting a slowdown in overall business growth. Additionally, numerous risks, such as competition, patient acquisition and retention difficulties, and potential dilution, further exacerbate concerns regarding the company's path to profitability.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.